Repositioning Candidate Details
| Candidate ID: | R0983 |
| Source ID: | DB06329 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | RG-7795 |
| Synonyms: | -- |
| Molecular Formula: | C12H14N4O5S |
| SMILES: | CC(=O)O[C@@H]1C[C@@H](CO)O[C@H]1N1C(=O)SC2=CN=C(N)N=C12 |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 892498-64-5 |
| Molecular Weight: | 326.33 |
| DrugBank Indication: | Investigated for use/treatment in solid tumors. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ANA773 is an oral Toll like-receptor 7 (TLR7) prodrug agonist whose active metabolite promotes natural killer (NK) cell-mediated anti-tumor response by inducing cytokine secretion, enhanced cytolysis of tumor cells by natural killer (NK cells) and enhanced antibody-dependent cellular cytotoxicity (ADCC). ANA773 induced the secretion of interferon-alpha (IFN-alpha) and various other cytokines from human peripheral blood mononuclear cells (PBMC) cultured in vitro. Innate immunity provides the first line of defense against tumor cells by inducing a broad immune response that includes the secretion of cytokines and the stimulation of NK cells. NK cells mediate anti-tumor activity by multiple mechanisms. NK cells directly lyse tumor cells through the secretion of cytotoxic granules; they promote apoptosis through the production of interferon-gamma (IFN-gamma), and they enhance the anti-tumor response of other immune cells. NK cells are activated by diverse signals, including type I interferons. Large amounts of type I IFN are produced by plasmacytoid dendritic cells (pDCs) upon engagement of the pattern recognition receptor TLR7. The natural ligand for TLR7 is single stranded RNA, although a variety of small molecule agonists have also been discovered. |
| Targets: | Toll-like receptor 7 |
| Inclusion Criteria: | Therapeutic strategy associated |
